Filing Flows › Biodesix (BDSX) › Q2 2026 › vs Q2 2025
Biodesix (BDSX) Q2 2026 vs Q2 2025 (year over year)
Biodesix's revenue rose $6.8M (+34%) from $20.0M in Q2 2025 to $26.9M in Q2 2026. The biggest changes: Diagnostic Tests +$7.5M (+42%); Development Services −$608K (-29%).
Biodesix, Q2 2026: revenue $26.9M (+34% year over year), operating margin -20.1%, net loss $7.3M, operating cash flow −$1.6M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Diagnostic Tests | $25.3M | $17.9M | $7.5M | +42% |
| Development Services | $1.5M | $2.1M | −$608K | -29% |
| Revenue | $26.9M | $20.0M | $6.8M | +34% |
| Net loss | $7.3M | $11.5M | −$4.2M | -37% |
| Costs & expenses | $34.1M | $31.5M | $2.6M | +8% |
| Operating costs | $32.2M | $29.7M | $2.5M | +8% |
| Interest & other, net | $1.9M | $1.7M | $136K | +8% |
| Research & development | $3.1M | $3.3M | −$134K | -4% |
| SG&A | $24.3M | $22.4M | $1.9M | +8% |
| Other operating costs | $4.8M | $4.1M | $775K | +19% |
| Operating cash sources | $7.3M | $11.5M | −$4.2M | -37% |
| Depreciation & amortization | $1.4M | $1.4M | −$51K | -4% |
| Share-based compensation | $820K | $1.0M | −$219K | -21% |
| Working capital & other | $3.5M | $2.4M | $1.1M | +45% |
| Cash used in operations | $1.6M | $6.6M | −$5.0M | -76% |
| Net loss absorbed | $7.3M | $11.5M | −$4.2M | -37% |
Questions
How much did Biodesix's revenue grow year over year in Q2 2026?
Biodesix's revenue rose $6.8M (+34%) from $20.0M in Q2 2025 to $26.9M in Q2 2026.
What drove Biodesix's revenue change in Q2 2026?
Diagnostic Tests +$7.5M (+42%); Development Services −$608K (-29%).